Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (BHC) announced that its aesthetics business, Solta Medical, surpassed 10 million treatments worldwide across its portfolio. Separately, Solta’s Thermage brand surpassed 7 million tips globally.
Solta’s portfolio includes Thermage, Fraxel, Clear + Brilliant Touch and VASERlipo. Its devices are used for skin tightening without surgery, laser skin resurfacing and minimally invasive body contouring. Bausch Health said it is focused on building on Solta’s global presence and supporting the business’s continued growth.
Bausch Health (NYSE: BHC; TSX: BHC) and its Salix business will present research on severe alcohol-associated hepatitis at The Liver Meeting 2026.
The meeting runs November 5–9 in Denver, Colorado. The study evaluated 1,630 adults in the United States hospitalized with severe alcohol-associated hepatitis, a liver condition associated with alcohol use. Estimated overall survival at 12 months was 62.0%. Rehospitalization occurred in 31.4% of patients within 30 days of discharge and was estimated at 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.
Bausch Health (BHC) announced that its subsidiary Bausch Health Americas will redeem approximately $643 million in outstanding notes.
The full redemption covers the subsidiary's 8.500% Senior Notes due 2027 and is scheduled for November 30, 2026, using cash on hand. Bausch Health Americas will issue an irrevocable redemption notice dated October 29, 2026, to record holders. The indenture governing the notes will be terminated in connection with the redemption. Payment and surrender of the notes will take place through the Depository Trust Company's procedures.
Bausch Health (BHC) has authorized a share repurchase program allowing purchases of common shares for up to US$50 million.
The company says the primary objective is to manage potential dilution from future employee equity-based compensation. Purchases may begin November 3, 2026, and the program will end no later than November 3, 2027. Repurchases cannot exceed 5% of the 374,266,716 common shares outstanding as of October 23, 2026. Shares acquired will be cancelled. Purchases may occur in U.S. open markets at prevailing prices, subject to a maximum price set by the board; actual purchases depend on market conditions, legal requirements and other factors.
Bausch Health (BHC) reported third-quarter 2026 revenue of $2.94 billion, with higher earnings and an increase in full-year guidance. Revenue rose 10% reported and 8% organically, excluding currency and portfolio changes. GAAP net income attributable to Bausch Health reached $436 million versus $179 million a year earlier; diluted earnings per share rose to $1.15 from $0.48. Operating cash flow increased to $813 million from $405 million.
The company now forecasts 2026 consolidated revenue of $10.975–$11.175 billion and adjusted EBITDA, a non-GAAP earnings measure, of $4.315–$4.415 billion. The board authorized a $50 million buyback primarily to offset anticipated management equity-award dilution in 2027. Solta revenue rose 18% reported but fell 4% organically. Despite quarterly growth, the nine-month net loss attributable to Bausch Health was $729 million, versus income of $269 million a year earlier.
Bausch Health (BHC) and its Salix gastroenterology business announced improved cirrhosis care adherence in a six-month community-practice pilot study. The study included 4,251 patients across five practices and evaluated a standardized care pathway supported by population health analytics.
Office visit adherence rose from 46.9% to 51.1%, while recommended laboratory monitoring increased from 61.5% to 63.5%. Beta-blocker treatment among patients with varices rose from 47.2% to 48.8%. Medication treatment to reduce recurrence of hepatic encephalopathy, a brain-function complication of liver disease, increased from 60.2% to 64.9%. Enrollment in chronic care management/principal care management programs rose from 11.7% to 12.8%.
The findings were accepted for presentation at the ACG annual meeting in Nashville, October 9–14, 2026. They remain preliminary pending presentation and further evaluation in peer-reviewed publications.
Bausch + Lomb (BLCO) appointed board chairman Thomas J. Appio interim chief executive officer, effective immediately, replacing departing CEO Brent Saunders. Appio will also remain CEO of parent company Bausch Health (BHC). Saunders and the Bausch + Lomb board mutually agreed on his departure.
Based on preliminary third-quarter results, both companies expect to raise full-year 2026 adjusted EBITDA excluding acquired in-process research and development guidance, a non-GAAP earnings measure. They attribute the expected increases to third-quarter business performance and anticipated better performance for the remainder of 2026. Additional details are due with third-quarter results on October 28. Bausch Health, excluding Bausch + Lomb, has delivered 13 consecutive quarters of year-over-year revenue and adjusted EBITDA growth under Appio.
Bausch Health (BHC) will release its third quarter 2026 financial results after market close on October 28, 2026.
A live conference call and webcast will follow at 5:00 p.m. U.S. EDT to discuss results and provide a business update. Materials will be available on the company's Investor Relations website before the call, with a replay available afterward.
Bausch Health (BHC) and Belgian skincare company YUN are expanding their strategic collaboration to Mexico and additional EMEA markets following a 2025 launch in Poland.
In Poland, Bausch Health broadened its dermatology portfolio to include YUN's eczema-prone skincare solutions alongside existing acne-prone products. Geographic rollout now covers YUN's acne- and eczema-prone skincare in the Czech Republic, Slovakia, Ukraine and Bulgaria, with YUN skincare also introduced in Mexico. The companies expect the next launch phase in Kazakhstan in October 2026, aiming to increase access to science-led, microbiome-friendly probiotherapeutical skincare solutions.
Bausch Health (NYSE:BHC) and its aesthetics business, Solta Medical, announced that the next-generation Fraxel FTX skin resurfacing laser is now available to health care practitioners in Australia starting September 1, 2026. The system builds on more than 20 years of Fraxel technology, combining dual wavelengths (1550 nm and 1927 nm) to target both superficial and deeper skin layers for dermatologic procedures and skin resurfacing.
Key features include Intelligent Optical Tracking with AccuTRAC to support uniform energy delivery, an ergonomic handpiece reduced in size and weight, integrated cooling for patient comfort, a refreshed guided treatment interface, and an updated console design. According to Bausch Health, Fraxel FTX is indicated for multiple conditions, including actinic keratosis, lentigos, ephelides, dyschromia including melasma, periorbital wrinkles, acne scars and surgical scars, with detailed contraindications, warnings, and potential adverse events provided for safe clinical use.